Simultaneous color-coded imaging to distinguish cancer "stem-like" and non-stem cells in the same tumor

Journal of Cellular Biochemistry

Volumn 111, Issue 4, 2010, Pages 1035-1041

  Suetsugu, Atsushi ^a,b,c   Osawa, Yosuke ^c   Nagaki, Masahito ^c   Moriwaki, Hisataka ^c   Saji, Shigetoyo ^c   Bouvet, Michael ^b   Hoffman, Robert M ^a,b  

^a ANTICANCER INC   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer stem cells; CD133; Chemotherapy; Color coded imaging; GFP; Hepatocellular carcinoma; Nude mice; RFP

Indexed keywords

BEVACIZUMAB; CD133 ANTIGEN; CISPLATIN; GREEN FLUORESCENT PROTEIN; RED FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL ISOLATION; CELL LABELING; CELL PROLIFERATION; CELL SELECTION; CHEMOSENSITIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CELL COUNT; CELL LINE, TUMOR; CELL SEPARATION; COCULTURE TECHNIQUES; COLOR; DIAGNOSTIC IMAGING; DRUG RESISTANCE, NEOPLASM; GLYCOPROTEINS; GREEN FLUORESCENT PROTEINS; HUMANS; LIVER NEOPLASMS; LUMINESCENT PROTEINS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PEPTIDES;

MUS MUSCULUS;

EID: 78049252349     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22792     Document Type: Article

References (31)

1. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. 2005. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11: 1154-1159.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
4. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. 2005. Opinion: The origin of the cancer stem cell: Current controversies and new insights. Nat Rev Cancer 5: 899-904.
5. Bonnet D, Dick JE. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
6. Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D, Camussi G. 2005. Isolation of renal progenitor cells from adult human kidney. Am J Pathol 166: 545-555.
7. Chishima T, Miyagi Y, Wang X, Yamaoka H, Shimada H, Moossa AR, Hoffman RM. 1997. Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res 57: 2042-2047.
8. Dean M, Fojo T, Bates S. 2005. Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
9. Donnenberg VS, Landreneau RJ, Donnenberg AD. 2007. Tumorigenic stem and progenitor cells: Implications for the therapeutic index of anti-cancer agents. J Control Release 122: 385-391.
10. Hoffman RM. 2005. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 5: 796-806.
11. Hoffman RM, Yang M. 2006a. Subcellular imaging in the live mouse. Nat Protoc 1: 775-782.
12. Hoffman RM, Yang M. 2006b. Color-coded fluorescence imaging of tumor-host interactions. Nat Protoc 1: 928-935.
13. Hoffman RM, Yang M. 2006c. Whole-body imaging with fluorescent proteins. Nat Protoc 1: 1429-1438.
14. Jaszai J, Fargeas CA, Florek M, Huttner WB, Corbeil D. 2007. Focus on molecules: Prominin-1 (CD133). Exp Eye Res 85: 585-586.
15. Jordan CT, Guzman ML, Noble M. 2006. Cancer stem cells. N Engl J Med 355: 1253-1261.
16. Kishimoto H, Zhao M, Hayashi K, Urata Y, Tanaka N, Fujiwara T, Penman S, Hoffman RM. 2009a. In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci USA 106: 14514-14517.
17. Kishimoto H, Urata Y, Tanaka N, Fujiwara T, Hoffman RM. 2009b. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther 8: 3001-3008.
18. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. 2007. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556.
19. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS. 2007. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-3161.
20. Mizrak D, Brittan M, Alison MR. 2008. CD133: Molecule of the moment. J Pathol 214: 3-9.
21. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA. 2007. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946.
22. O'Brien CA, Pollett A, Gallinger S, Dick JE. 2007. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
23. Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
24. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. 2007. Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
25. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. 2006. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351: 820-824.
26. Tome Y, Tsuchiya H, Hayashi K, Yamauchi K, Sugimoto N, Kanaya F, Tomita K, Hoffman RM. 2009. In vivo gene transfer between interacting human osteosarcoma cell lines is associated with acquisition of enhanced metastatic potential. J Cell Biochem 108: 362-367.
27. Toren A, Bielorai B, Jacob-Hirsch J, Fisher T, Kreiser D, Moran O, Zeligson S, Givol D, Yitzhaky A, Itskovitz-Eldor J, Kventsel I, Rosenthal E, Amariglio N, Rechavi G. 2005. CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells 23: 1142-1153.
28. Yamauchi K, Yang M, Jiang P, Xu M, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM. 2006. Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res 66: 4208-4214.
29. Yang M, Baranov E, Jiang P, Sun FX, Li XM, Li L, Hasegawa S, Bouvet M, Al-Tuwaijri M, Chishima T, Shimada H, Moossa AR, Penman S, Hoffman RM. 2000. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci USA 97: 1206-1211.
30. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. 1997. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012.
31. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J. 2007. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.